MET and neoplasm: In support of this, Nakagawa et al. (2010) reported that dual inhibition of c-Met and VEGFR2 led to tumor regression, reduced angiogenesis, and prolonged survival of tumor-bearing mice in an in vivo model of gastric cancer (Nakagawa et al., 2010).